<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298749</url>
  </required_header>
  <id_info>
    <org_study_id>GX-P1-001</org_study_id>
    <nct_id>NCT04298749</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of GX-P1 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-P1 After Single IV Infusion in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, double-blind, placebo-controlled, phase I study with healthy&#xD;
      male volunteers receiving ascending single dose of GX-P1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Actual">June 7, 2021</completion_date>
  <primary_completion_date type="Actual">June 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by AEs</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Safety and tolerability will be assessed by monitoring AEs and performing physical/clinical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, Maximum observed concentration</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, Time to maximum observed concentration</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Time to maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2, Elimination half life of GX-P1</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Elimination half life of GX-P1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf), Area under the concentration-time curve from time zero extrapolated to infinite time</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Area under the concentration-time curve from time zero extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of T cells</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Change of T cell subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent anti-drug antibody(ADA) formation</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Treatment Emergent anti-drug antibody(ADA) formation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>GX-P1 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-P1 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-P1 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-P1 dose level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 1)</intervention_name>
    <description>GX-P1 dose level 1 or placebo</description>
    <arm_group_label>GX-P1 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 2)</intervention_name>
    <description>GX-P1 dose level 2 or placebo</description>
    <arm_group_label>GX-P1 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-P1 or Placebo (dose level 3)</intervention_name>
    <description>GX-P1 dose level 3 or placebo</description>
    <arm_group_label>GX-P1 dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of understanding and complying with the requirements of the study and have&#xD;
             voluntarily signed the informed consent form (ICF)&#xD;
&#xD;
          2. Healthy male volunteers aged 19-45 years within screening periods&#xD;
&#xD;
          3. Body weight of 50-90 kg, and body mass index (BMI) of 18.0-30.0 kg/m2&#xD;
&#xD;
          4. Healthy subjects as determined by medical history, physical examination vital signs,&#xD;
             ECG and clinical laboratory testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinical significant pancreatic, hepatic, renal, gastrointestinal, cardiovascular,&#xD;
             respiratory, hematological, central nervous system disease or other significant&#xD;
             diseases which might influence either the safety of the subject or the absorption,&#xD;
             metabolism or excretion of the active agent under investigation&#xD;
&#xD;
          2. History of or current disease evidence including malignant tumor&#xD;
&#xD;
          3. History of allergy/hypersensitivity or ongoing allergy/hypersensitivity to any drug&#xD;
&#xD;
          4. Have participated in another clinical trial with investigational drug within 180 days&#xD;
             prior to screening period&#xD;
&#xD;
          5. Positive for HCV antibody, HBsAg, or HIV antibody at screening period&#xD;
&#xD;
          6. Other clinically significant abnormalities which make subject unsuitable for inclusion&#xD;
             this study judged by investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

